1. Sternberg CN, Yagoda A, Scher HI, Watson RC, Herr HW, Morse MJ, et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol. 1988. 139:461–469.
2. Tannock I, Gospodarowicz M, Connolly J, Jewett M. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience. J Urol. 1989. 142:289–292.
3. Pectasides D, Pectasides E, Economopoulos T. Systemic therapy in metastatic or recurrent endometrial cancer. Cancer Treat Rev. 2007. 33:177–190.
4. Jung JH, Lee SJ, Kim HW, Cho SY, Kim SW, Lee CB, et al. Efficacy and toxicity of gemcitabine plus cisplatin chemotherapy in advanced urothelial cancer. Korean J Urol. 2003. 44:739–744.
5. Yoon DJ, Chang SG. Efficacy and toxicity of gemcitabine based chemotherapy for advanced urothelial cancer. Korean J Urol. 2002. 43:7–13.
6. Jang CS, Cho JS, Lee SK, Lee YG, Yang DY, Kim SY, et al. Hematologic toxicity of gemcitabine and cisplatin combination therapy in advanced urothelial cancer. Korean J Urol. 2003. 44:672–676.
7. Khaled HM, Hamza MR, Mansour O, Gaafar R, Zaghloul MS. A phase II study of gemcitabine plus cisplatin chemotherapy in advanced bilharzial bladder carcinoma. Eur J Cancer. 2000. 36:Suppl 2. 34–37.
8. Yagoda A. Progress in treatment of advanced urothelial tract tumors. J Clin Oncol. 1985. 3:1448–1450.
9. Igawa M, Ohkuchi T, Ueki T, Ueda M, Okada K, Usui T. Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer. J Urol. 1990. 144:662–665.
10. Dimopoulos MA, Finn L, Logothetis CJ. Pattern of failure and survival of patients with metastatic urothelial tumors relapsing after cis-platinum-based chemotherapy. J Urol. 1994. 151:598–600.
11. Roth BJ. Chemotherapy for advanced bladder cancer. Semin Oncol. 1996. 23:633–644.
12. Saxman SB, Propert KJ, Einhorn LH, Crawford ED, Tannock I, Raghavan D, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1997. 15:2564–2569.
13. Lee CK, Choi S, Kim JC, Rhew HY. A retrospective study comparing M-VAC and CISCA chemotherapy in advanced urothelial transitional cell carcinoma. Korean J Urol. 1994. 35:1339–1346.
14. Dodd PM, Bajorin DF. New chemotherapy regimens for metastatic bladder cancer. Curr Opin Urol. 1998. 8:413–418.
15. Sternberg CN. Gemcitabine in bladder cancer. Semin Oncol. 2000. 27(1):Suppl 2. 31–39.
16. Kaufman D, Raghavan D, Carducci M, Levine EG, Murphy B, Aisner J, et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol. 2000. 18:1921–1927.
17. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000. 18:3068–3077.
18. Stadler WM, Hayden A, von der Maase H, Roychowdhury D, Dogliotti L, Seymour L, et al. Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Urol Oncol. 2002. 7:153–157.
19. Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999. 17:3173–3181.
20. Loehrer PJ, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992. 10:1066–1073.
21. Geller NL, Sternberg CN, Penenberg D, Scher H, Yagoda A. Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. Cancer. 1991. 67:1525–1531.
22. Als AB, Sengelov L, von der Maase H. Long-term survival after gemcitabine and cisplatin in patients with locally advanced transitional cell carcinoma of the bladder: focus on supplementary treatment strategies. Eur Urol. 2007. 52:478–486.
23. Moore MJ, Winquist EW, Murray N, Tannock IF, Huan E, Bennett K, et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trial Group. J Clin Oncol. 1999. 17:2876–2881.
24. Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol. 1997. 15:3394–3398.
25. Roberts JT, von der Maase H, Sengelov L, Conte PF, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer. Ann Oncol. 2006. 17:Suppl 5. v118–v122.